Pharmigene Balance Sheet Health
Financial Health criteria checks 1/6
Pharmigene has a total shareholder equity of NT$327.2M and total debt of NT$554.4M, which brings its debt-to-equity ratio to 169.4%. Its total assets and total liabilities are NT$917.6M and NT$590.3M respectively.
Key information
169.4%
Debt to equity ratio
NT$554.40m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$48.97m |
| Equity | NT$327.24m |
| Total liabilities | NT$590.31m |
| Total assets | NT$917.55m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 7595's short term assets (NT$127.0M) exceed its short term liabilities (NT$56.5M).
Long Term Liabilities: 7595's short term assets (NT$127.0M) do not cover its long term liabilities (NT$533.8M).
Debt to Equity History and Analysis
Debt Level: 7595's net debt to equity ratio (154.5%) is considered high.
Reducing Debt: 7595's debt to equity ratio has increased from 0% to 169.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 7595 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 7595 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.